Dr. Vasishta and Long Term Remission of Relapsing-Remitting MS

In the article, “Stem cell transplants may induce long-term remission of multiple sclerosis”, published by the National Institutes of Health, the author divulges information about the effectiveness of a new treatment for multiple sclerosis. This treatment is called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant or HDIT/HCT. This experimental treatment suppresses the immediate effects of relapsing-remitting MS and prevents any future progression of the disease. The treatment does this by removing diseased cells and resetting the immune system. HDIT/HCT treatment works by having a doctor obtain a sample of the patient’s blood-forming stem cells, deplete the immune system with a high dose of chemotherapy, and then reinsert the patient’s stems cells which revive their immune system. This is a way of restarting the patient’s immune system. By going through with the treatment, patient does carry the risk of becoming infected.

The results of this treatment have varied slightly but most participants have seen their relapsing-remitting MS stabilized. Although the majority have seen positive results, three of the participants did die but their deaths were not a result of the participation in the trial treatment. Most trial participants have remained in remission five years after the trial treatment. This is a very positive outlook on the future treatments that will build off of the advancements of HDIT/HCT.

New Jersey based Dr. Shiva Gopal Vasishta, is a neurology specialist and obtained his degree from Government Medical College. Dr. Shiva Gopal Vasishta currently practices out of Kennedy Health System at the Cherry Hill Campus. Dr. Shiva Gopal Vashishta is a trained professional and has over 40 years of experience.

Dr. Shiva Gopal Vasishta’s practice is bilingual and supports both English and Spanish. He treats a wide spectrum of neurological diseases and offers treatment for MS. Dr. Shiva Gopal Vasishta is a doctor who could provide future treatment options for the now trial treatment HDIT/HCT.